Citations

Clear

214 citation(s) found for "Mukherjee, M".

Key points from the 2026 multisocietal acute pulmonary embolism guidelines: Perspectives of some SVM members on the writing committee
Porres‐Aguilar, Mateo , Piazza, Gregory, Barnes, Geoffrey D. , Mukherjee, Debabrata , Secemsky, Eric A. , Creager, Mark A. , Porres-Aguilar, Mateo , Creager, Mark A , Secemsky, Eric A , Mukherjee, Debabrata , Piazza, Gregory

Mayo Clinic

Vascular Medicine | August 13, 2026 | Volume: 31 | Issue: 4 | Pages: 617-620

10.1177/1358863x261469140 | PMID 42591043 Get It

Metabolomic Network Analysis Reveals Reorganization of Lipid and Steroid Programs Linked to Right Ventricular-Pulmonary Vascular Function in Pulmonary Hypertension
Clinton, Ivor, Coursen, Julie , Rosen, Darin , Suresh, Karthik , Balasubramanian, Aparna , Kolb, Todd M. , Damico, Rachel L. , Mathai, Stephen C. , Hsu, Steven , Mukherjee, Monica , Finet, J. Emanuel , Grünig, Gabriele , Rischard, Franz, Erzurum, Serpil C. , Beck, Gerald J. , Hill, Nicholas S. , Group, PVDOMICS Study, Clinton, Ivor W , Coursen, Julie C , Rosen, Darin T , Barnard, John , Hemnes, Anna , Leopold, Jane A , Horn, Evelyn M , Rosenzweig, Erika B , Frantz, Robert P , Erzurum, Serpil C , King, Wendy , Beck, Gerald J , Hill, Nicholas S , Hassoun, Paul M , Simpson, Catherine E , Mathai, Stephen C , Balasubramanian, Aparna , Mukherjee, Monica , Hsu, Steven , Barnard, John , Hemnes, Anna R. , Leopold, Jane A. , Horn, Evelyn M. , Rosenzweig, Erika B. , Rischard, Franz , Frantz, Robert P. , King, Wendy C. , Hassoun, Paul M. , Simpson, Catherine E. , Group, PVDOMICS Study

Mayo Clinic

No container title available | June 22, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.06.16.732773 | PMID 42395385 Get It

ABSTRACT Background Pulmonary arterial hypertension (PAH) is characterized by circulating metabolic alterations, but whether these reflect disease-specific metabolic programs or reorganization of normal metabolic architecture, and how they relate to right ventricular-pulmonary vascular function (RV-PV), remains unclear. We hypothesized that the PAH metabolome is organized into biologically coherent, co-regulated metabolic modules whose relationships to RV-PV function would provide insight into known and novel metabolic pathways. Methods We applied weighted gene co-expression network analysis (WGCNA) to untargeted metabolomic data from 412 PAH patients enrolled in the multicenter PVDOMICS study. Module preservation analysis was performed in 85 healthy controls, with external replication in an independent single-center pulmonary hypertension cohort of 89 patients. Results WGCNA identified 16 distinct metabolic modules organized around biologically coherent programs. A coherent fatty acid axis, spanning substrate pools, β-oxidation intermediates, and conjugated fatty acid disposal products, formed a central organizing structure, with downstream fatty acid oxidation modules strongly associated with adverse hemodynamics and worse RV-pulmonary artery (PA) coupling. Acylcholine-enriched and 5α-reduced androgen metabolite modules were associated with favorable hemodynamic indices. Module architecture was largely preserved in healthy controls, with subtle disease-associated modular reorganization, rather than emergence of novel modules, observed in PAH. Core modules were recovered in the replication cohort with conserved hub metabolites. Conclusions These findings establish a systems-level framework demonstrating that PAH involves structured intensification and reorganization of interconnected metabolic programs associated with favorable and adverse RV-PV phenotypes. This work provides new insight into the metabolic architecture underlying PAH and identifies coordinated metabolic pathways linked to pulmonary vascular and right ventricular function.
Phenotypic Characterization of Unclassified Pulmonary Hypertension
Frantz, Robert P. , Egbe, Alexander C. , Miranda, William R. , Asokan, Aneesh K , Hassoun, Paul M. , Hemnes, Anna R. , Horn, Evelyn M. , Leopold, Jane A. , Rischard, Franz, Hill, Nicholas S. , Erzurum, Serpil C. , Finet, J. Emanuel , Nishimura, Rick , Frantz, Robert P , Egbe, Alexander C , Miranda, William R , Hassoun, Paul M , Hemnes, Anna , Horn, Evelyn M , Leopold, Jane A , Rosenzweig, Erika B , Hill, Nicholas S , Erzurum, Serpil C , Finet, J Emanuel , Mukherjee, Monica , Tang, W H Wilson , Borlaug, Barry A , Reddy, Yogesh N.V. , Rischard, Franz , Rosenzweig, Erika B. , Mukherjee, Monica , Tang, W.H. Wilson , Nair, K. Sreekumaran , Borlaug, Barry A.

Mayo Clinic

Circulation: Heart Failure | June 19, 2026 | Volume: 19 | Issue: 7 | Pages: No page available

10.1161/circheartfailure.125.014480 | PMID 42318624 Get It

BACKGROUND: Some symptomatic patients manifest pulmonary hypertension (PH), despite normal pulmonary vascular resistance and pulmonary artery wedge pressure—a condition termed unclassified PH. Although hypothesized to reflect increased flow as seen in congenital heart disease, broader clinical implications remain unknown. METHODS: The current analysis included pulmonary vascular disease phenomics participants with either no PH or unclassified PH who underwent dynamic right heart catheterization and transpulmonary metabolomics. In a validation cohort, patients with no PH or unclassified PH underwent exercise right heart catheterization. In exploratory cohorts to understand the impact of increased flow, the prevalence of unclassified PH was assessed in (1) adult congenital heart disease and (2) high output heart failure. RESULTS: The overall prevalence of unclassified PH in pulmonary vascular disease phenomics (n=1046) and the validation cohort (n=1202) was 7.8% (175/2248), which was comparable to the 6.6% (66/1005) prevalence in adult congenital heart disease (n=1005), and lower than high output heart failure (n=159, prevalence 14.5% [23/159]; P =0.006). Increased flow occurred in a minority of unclassified PH from both pulmonary vascular disease phenomics (28%; 15/53) and the validation cohort (11%; 13/122). Unclassified PH (n=53) was associated with greater adiposity, higher heart failure with preserved ejection fraction (HFpEF)–age, body mass index, atrial fibrillation score probability, and more left heart remodeling compared with those with no PH (n=216). Metabolomics revealed lower glycine metabolites in unclassified PH indicative of metabolic dysfunction. Left heart remodeling, quality of life, exercise capacity, and glycine levels were all abnormal in unclassified PH relative to healthy controls (n=96). In the validation cohort, pulmonary artery wedge pressure, pulmonary vascular resistance, and pulmonary artery compliance were subtly abnormal at rest in unclassified PH (n=122) compared with no PH (n=312). With exercise testing, 59% (72/122) with unclassified PH had exertional pulmonary artery wedge pressure elevation consistent with undiagnosed HFpEF. CONCLUSIONS: The presence of PH without obvious cause most often reflects subclinical left heart and metabolic dysfunction consistent with unrecognized early-stage HFpEF. Dynamic provocation during right heart catheterization can unmask unrecognized HFpEF in over half of unclassified PH, which may help guide appropriate initiation of proven HFpEF therapies to improve symptoms and functional status. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02980887.
Predictors of hospital length of stay, discharge disposition, and readmission after craniopharyngioma surgery: a multicenter study from the RAPID database
Tenhoeve, Samuel A. , Tang, Anthony , Orton, Cody , Gautam, Diwas, Abdul-Rahman, Nana-Hawwa, Silverstein, Julie M., Kim, Albert H., Evans, James J., Barkhoudarian, Garni, Fernandez-Miranda, Juan C., Pacione, Donato , Kim, Won, Bergsneider, Marvin, Zada, Gabriel, Kshettry, Varun R., Wu, Kyle C., Benjamin, Carolina G., Gompel, Jamie J. Van, Catalino, Michael P., Mamelak, Adam N., Zwagerman, Nathan T., Cheok, Stephanie K., Little, Andrew S., Zenonos, Georgios A., Karsy, Michael, Morshed, Ramin A., Blackburn, Spiros L., Mukherjee, Debraj, Beer-Furlan, Andre, Couldwell, William T., Gardner, Paul A., Rennert, Robert C., Karsy, Michael , Mukherjee, Debraj , Barkhoudarian, Garni , Van Gompel, Jamie, Palit, Sandhya R. , Mukherjee, Debraj , Karsy, Michael , Gautam, Diwas , Abdul‐Rahman, Nana‐Hawwa , Silverstein, Julie , Kim, Albert H , Evans, James J., Fernandez‐Miranda, Juan C. , Bergsneider, Marvin , Chicoine, Michael , Zada, Gabriel , Kshettry, Varun R. , Gompel, Jamie J. Van , Catalino, Michael Paul, Mamelak, Adam N, Zwagerman, Nathan T. , Cheok, Stephanie , Little, Andrew S. , Zenonos, Georgios A. , Morshed, Ramin A. , Blackburn, Spiros L., Beer‐Furlan, André , Couldwell, William T. , Gardner, Paul A. , Rennert, Robert C

Mayo Clinic

Neurosurgical Focus | May 27, 2026 | Volume: 60 | Issue: 6 | Pages: E6

10.3171/2026.2.focus251047 | PMID 42224727 Get It

OBJECTIVE Craniopharyngiomas are benign intracranial tumors that can be difficult to manage operatively and often result in postoperative complications and prolonged recovery. Understanding the factors that influence length of stay (LOS), discharge disposition, and readmission can guide perioperative planning and patient counseling. The authors examined the clinical, radiographic, and surgical predictors of extended LOS (eLOS), nonhome discharge, 90-day readmission, and hospitalization ratio (HR) after craniopharyngioma resection using a large, multicenter cohort. METHODS A retrospective analysis was conducted using the Registry of Adenomas of the Pituitary and Related Disorders database, encompassing 469 patients who underwent craniopharyngioma resection at 14 US academic centers from 2011 to 2025. Patients were stratified by 4 outcomes: eLOS (> 75th percentile), discharge to home versus skilled nursing facility/rehabilitation, 90-day hospital readmission, and hospitalization ratio (i.e., integration of initial and readmission LOS). Multivariable logistic regression models identified independent predictors for each outcome among patient and surgical variables. RESULTS An eLOS (> 10 days) was independently associated with preoperative memory loss (OR 3.75, 95% CI 1.95–7.21), gait imbalance (OR 5.90, 95% CI 1.53–22.70), and postoperative complications (OR 4.07, 95% CI 2.34–7.06). The use of a nasoseptal flap was protective against an eLOS (OR 0.52, 95% CI 0.28–0.93). Discharge to home was predicted by an endoscopic approach (OR 3.87, 95% CI 1.78–8.44) and postoperative intact thirst (OR 2.22, 95% CI 1.05–4.66) and negatively predicted by preoperative diabetes mellitus (OR 0.21, 95% CI 0.09–0.50), LOS (OR 0.87, 95% CI 0.84–0.91), and postoperative cognitive dysfunction (OR 0.30, 95% CI 0.13–0.72). Among 385 patients with follow-up data, a 90-day readmission was independently associated with postoperative complications (OR 5.62, 95% CI 3.12–10.13), preexisting coronary artery disease (OR 4.30, 95% CI 1.46–12.69), and postoperative cognitive dysfunction (OR 3.33, 95% CI 1.76–6.44). A higher HR was associated with diabetes mellitus (unstandardized B 0.059, 95% CI 0.010–0.108, p = 0.02), postoperative complications (unstandardized B 0.054, 95% CI 0.021–0.086, p = 0.001), and postoperative cognitive dysfunction (unstandardized B 0.049, 95% CI 0.006–0.092, p = 0.02). Tumor pathologic subtype and size, prior treatment, extent of resection, and surgeon experience were not directly predictive of outcomes. CONCLUSIONS Cognitive and functional status, systemic comorbidities, and postoperative complications, in addition to surgical approach, are important predictors of the early clinical course after craniopharyngioma surgery. Early identification of high-risk patients may help to guide treatment decisions, improve discharge planning, and reduce healthcare utilization.
The landscape of antibody production systems: recombinant expression for research, diagnostics and therapy
Al-Halabi-Frenzel, Laila, Demiral, Seyhan, Frenzel, André , Gnann, Dianne Celine , Keitel, Martha Charlotte-Elisabeth, Lehmler, Nina, Rauls, Justus, Schirrmann, Thomas , Stańczyk, Piotr Grzegorz, Terbrack, Jan, Westerhoff, Sofie, Dübel, Stefan, Hust, Michael, Dübel, Stefan , Wenzel, Esther Veronika , Mukherjee, Tarushyam , Steinke, Stephan , Schubert, Maren , Hust, Michael , Bertoglio, Federico

Mayo Clinic

Frontiers in Bioengineering and Biotechnology | May 20, 2026 | Volume: 14 | Issue: No issue available | Pages: No page available

10.3389/fbioe.2026.1765764 | PMID 42245239 Get It

Over the past three decades, the emergence of recombinant antibodies has positioned them as the fastest-growing class of therapeutic proteins and as well as crucial reagents for both diagnostics and specific research applications. The industrial production of most therapeutic antibodies currently relies on mammalian cell lines, primarily Chinese Hamster Ovary (CHO) cells, which remain the gold standard in biopharmaceutical manufacturing due to their exceptionally high production yields, robustness, regulatory acceptance, and consistent product quality. Nevertheless, new approaches using specifically adapted expression systems are emerging. These new host organisms enable the production of antibodies with posttranslational modifications that closely resemble those found in the human system, without the need for animal-derived source materials. For diagnostic and research purposes, a broad range of production systems has been developed. These include Gram-negative and Gram-positive bacteria, yeasts, filamentous fungi, insect cell lines, and transgenic plants. Additionally, smaller single domain antibodies and bispecific fragments that do not require glycosylation can be successfully produced in bacteria for therapeutic applications. Some of these molecules have already been approved by regulatory authorities in the European Union and the United States, and several more are currently in clinical trials. This review therefore focuses on the broad and evolving landscape of recombinant antibody production systems and their applicability across various fields.
D16-06 Metabolomic Profiling Differentiates PAH-like and ILD-like Phenotypes in Interstitial Lung Disease-related Pulmonary Hypertension
Khan, S L, Lammi, M R, Danoff, S K, Balasubramanian, A, Kolb, T M, Mukherjee, M, Finet, J, Grunig, G, Jellis, C L, Kwon, D, Mehra, R, Park, M M, Barnard, J, Comhair, S A, Hemnes, A R, Leopold, J A, Horn, E M, Rosenzweig, E Berman, Rischard, F P, Frantz, R P, Erzurum, S C, Tang, W, Beck, G J, Hill, N S, Hassoun, P M, Mathai, S C, Simpson, C, Group, The PVDOMICS Study, Mathai, Stephen C. , Mathai, Stephen C , Lammi, Matthew R. , Danoff, S.K., Balasubramanian, A, Kolb, T M, Finet, J. Emanuel , Grünig, Gabriele , Jellis, C.L., Kwon, D, Leopold, Jane A. , Rosenzweig, E.B., Rischard, Franz , Frantz, Robert P. , Hassoun, Paul M.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.5877 Get It

Abstract Introduction Interstitial lung disease-associated pulmonary hypertension (ILD-PH) is a clinically challenging entity that lies on a pathophysiologic spectrum between pulmonary arterial hypertension (PAH) and interstitial lung disease (ILD). We compared the metabolomes of patients with ILD-PH to those with PAH and ILD to characterize the PAH-ILD axis and determine whether ILD-PH patients can be phenotyped based on their metabolomic similarity to PAH. Methods Using untargeted metabolomics profiles from patients with PAH, ILD, and ILD-PH in the large, U.S.-based, NIH-funded, multi-center PVDOMICS cohort, we trained an anchor-based classifier on PAH and ILD metabolomes using supervised PLS-DA with a 75/25 train/test split. Primary and secondary PH or risk-group classifications in PVDOMICS were based on expert adjudication of clinical data including right heart catheterization hemodynamics, pulmonary function testing, chest imaging, and laboratory results. We then applied the trained model to each ILD-PH patient to assign a PAH similarity score. We classified patients as having a PAH-like or ILD-like metabolomic phenotype using an optimal PAH similarity score cutoff of 0.5 then compared PAH metabolomic similarity to expert-adjudicated primary and secondary WSPH classifications in PVDOMICS. We implemented FELLA, a network-based metabolomics enrichment method, to holistically characterize the biologic underpinnings of PAH, ILD-PH, and ILD metabolomes. Results We analyzed 244 patients with PAH, 54 with ILD, and 47 with ILD-PH. The anchor-based classifier demonstrated high train-test performance with a c-statistic of 0.81 and 78% agreement with expert-adjudicated diagnoses. Among the ILD-PH patients, 23 were classified as PAH-like and 24 as ILD-like (74% agreement with expert adjudication, Cohen’s kappa 0.49, Hedge’s g estimate of 0.86). FELLA enrichment revealed core glycolytic and bioenergetic pathways were enriched in both pure PAH and ILD-PH. Comparison of diffusion Z-scores between groups demonstrated subtle but biologically coherent differences in several reaction-level nodes, including lactate, NADPH oxidoreductase, and phosphofructokinase, which were enriched in ILD-PH. Conclusion Patients with ILD-PH demonstrate clinically relevant metabolomic phenotypes. Examination of the network biology underlying ILD-PH may point to potential therapeutic targets in this vulnerable subgroup with lagging clinical outcomes. This abstract is funded by: Pulmonary Fibrosis Foundation PFF Scholars Program
C18-09 Prevalence and Impact of Liver Injury Across the Spectrum of Pulmonary Hypertension
Dubrock, H M, Frantz, R P, Beck, G J, Rosenzweig, E B, Erzurum, S C, Finet, J, Hassoun, P M, Hemnes, A R, Hill, N S, Horn, E M, Leopold, J A, Mathai, S C, Mukherjee, M, Rischard, F P, Borlaug, B, Reddy, Y N V, Group, PVDOMICS Study, Mathai, Stephen C. , Mathai, Stephen C , DuBrock, Hilary M. , Frantz, Robert P. , Rosenzweig, E.B., Finet, J. Emanuel , Hassoun, Paul M. , Leopold, Jane A. , Rischard, Franz , Borlaug, Barry A. , Reddy, Yogesh N.V. , Group, PVDOMICS Study

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.5761 Get It

Abstract Rationale The pathophysiology and clinical impact of liver injury in pulmonary hypertension (PH) is poorly understood. Liver injury in PH is often attributed to hepatic congestion, but some studies have failed to find strong associations with hemodynamics, suggesting alternative mechanisms. We sought to define the prevalence of liver injury and patterns of liver injury across the spectrum of PH and to determine whether patterns of liver injury were associated with clinical characteristics, hemodynamics and outcomes. Methods We performed an analysis of the PVDOMICS study, a multicenter, prospective, longitudinal cohort study that enrolled incident and prevalent patients with PH and disease comparators. The prevalence of liver injury, defined as aspartate or alanine aminotransferase (AST or ALT) or total bilirubin above the upper limit of normal, and different patterns of liver injury [hepatocellular (elevated AST or ALT with normal bilirubin), cholestatic (elevated bilirubin) and no liver injury] was defined among participants with known or suspected PH. Associations between patterns of liver injury with demographics, hemodynamics, right ventricular function, exercise capacity and quality of life (QoL) were assessed. We used Cox proportional hazards models adjusted for age and sex to assess the association of liver injury patterns with transplant-free survival. Results Liver injury was present in 27.8% (288/1036) of participants (19.0% cholestatic and 8.8% hepatocellular). Patients with liver injury were less likely to be female and have prevalent disease with differences in PH classification (Table 1). Patients with hepatocellular liver injury had a higher body mass index. A cholestatic liver injury pattern was most consistently associated with worse functional class, biventricular filling pressures, pulmonary vascular resistance, right ventricular function, natriuretic peptide elevation, exercise capacity, and REVEAL risk scores. Total bilirubin levels and right atrial pressure as a marker of systemic congestion were weakly correlated (r2=0.02, p < 0.0001). Compared to no liver injury, cholestatic liver injury was associated with an increased risk of death in age and sex adjusted models (HR 1.6, 95% CI 1.3-2.1, p < 0.001) but hepatocellular liver injury was not (p > 0.05). Conclusions Liver injury is common among patients with known or suspected PH. In contrast to a hepatocellular injury pattern, a cholestatic liver injury pattern was most consistently associated with worse hemodynamics, exercise capacity, QoL and survival. However, the weak relationship between right atrial pressure and bilirubin suggests that systemic congestion alone is unlikely to completely explain cholestatic liver injury. Further study is needed to uncouple the pathophysiological basis of cholestasis in PH. This abstract is funded by: NHLBI
B106-12 Characteristics and Survival in Severely Dilated Pulmonary Artery Size in Pulmonary Hypertension
Ray, D N, Couch, T J, Beck, G J, Rosenzweig, E B, Carr, J J, Erzurum, S C, Frantz, R P, Hassoun, P M, Hill, N S, Horn, E M, Lempel, J K, Leopold, J A, Mukherjee, M, Nian, H, Rischard, F P, Schwalbach, K T, Terry, J G, Hemnes, A R, Group, The PVDOMICS Study, Ray, David N, Rosenzweig, E.B., Carr, J. Jeffrey , Frantz, Robert P. , Hassoun, Paul M. , Lempel, Jason K. , Leopold, Jane A. , Mukherjee, M, Rischard, Franz , Schwalbach, Kevin T. , Hemnes, Anna R.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.5743 Get It

Abstract Rationale Prior studies demonstrate pulmonary artery (PA) enlargement on computed tomography (CT) in pulmonary hypertension (PH). Some patients exhibit markedly enlarged or “aneurysmal” PA dilation, but its clinical relevance remains unclear. We aimed to characterize clinical characteristics, hemodynamics, and survival probability of patients with aneurysmal PA size. Methods Demographics, clinical characteristics, and CT imaging were obtained for individuals with group 1 or 2 PH and matched controls in the Pulmonary Vascular Disease Phenomics cohort. PA diameter was measured using Osirix software. PA diameter was categorized based on previously reported values as normal (<27 mm [females], <29 mm [males]), enlarged (27-39 mm [females], 29-39 mm [males]), or aneurysmal (≥40 mm). Outcomes included mean PA pressure (mPAP) on right heart catheterization (RHC) and time to death or heart/lung transplant. Associations with mortality and mPAP were evaluated using multivariable Cox and linear regression models, adjusting for age, sex, and BMI. Descriptive statistics are presented as median [IQR]. Results 690 subjects met the inclusion criteria for survival analysis (364 WSPH group 1 or matched comparator, 241 group 2 or comparator, 85 healthy control), with 594 undergoing RHC. PA diameter was normal in 163 participants, enlarged in 414, and aneurysmal in 113. Aneurysmal PA, compared with normal or enlarged PA, was associated with younger age (53 ± 14 vs 55 ± 16 and 59 ± 15 years, respectively; p < 0.001), non-White race (18.9% vs 8% and 17.2%; p = 0.034), pro-BNP (1950 ± 5708 vs 531 ±1651 and 110 ± 2258 pg/mL; p < 0.001), PH duration (6.78 ± 6.86 vs 2.24 ± 4.39 and 3.82 ± 5.47 years; p < 0.001), group 1 disease (77% vs 37% and 61%), and congenital heart disease (CHD)-PAH (10.6% vs 0.0% and 4.8%, p < 0.001). Aneurysmal PA subjects had higher mPAP (46 [36-57] vs 19 [16- 25] and 35 [28-47] mmHg, p < 0.001), pulmonary vascular resistance (PVR) (5.5 [3.6-9.4] vs 1.7 [1.0-2.3] and 4.1 [2.4-7.1] Woods units, p < 0.001), cardiac index (CI; 2.73 [2.34-3.29] vs 2.55 [2.13-2.98] and 2.52 [2.12-3.10] L/min/m2, p < 0.02) and likelihood of death or transplant (p < 0.001; Figure 1). Conclusion “Aneurysmal” PA was more common in younger, non-White subjects with longer WSPH group 1 disease duration, CHD, and higher pro-BNP levels. Aneurysmal PA was associated with elevated mPAP, PVR, and CI, and reduced likelihood of survival. These findings highlight the need to further elucidate the pathophysiology and prognostic implications of aneurysmal PA remodeling in PH. This abstract is funded by: NHLBI and the Pulmonary Hypertension Association
B106-01 Pulmonary Artery Imaging Changes in Group 3 Pulmonary Hypertension Differ by Etiology of Chronic Lung Disease
Couch, T J, Beck, G J, Rosenzweig, E Berman, Carr, J J, Erzurum, S C, Frantz, R P, Hassoun, P M, Hill, N S, Horn, E M, Lempel, J K, Leopold, J A, Mukherjee, M, Nian, H, Ray, D N, Rischard, F P, Schwalbach, K T, Terry, J G, Hemnes, A R, Group, The PVDOMICS Study, Rosenzweig, E.B., Carr, J. Jeffrey , Frantz, Robert P. , Hassoun, Paul M. , Lempel, Jason K. , Leopold, Jane A. , Mukherjee, M, Ray, David N, Rischard, Franz , Schwalbach, Kevin T. , Hemnes, Anna R.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.5733 Get It

Abstract Background We recently reported a strong association between CT markers of pulmonary artery (PA) dilation and mean PA pressure (mPAP) in subjects with World Symposium on Pulmonary Hypertension (WSPH) group 1 and 2 pulmonary hypertension (PH). The relationship between PA size and mPAP in subjects with WSPH group 3 PH, in which parenchymal changes may influence PA dilation, remains uncertain. We sought to investigate this relationship in subjects with and without PH who have significant parenchymal pulmonary disease or hypoxia. Methods We measured PA diameter and PA:aorta (PA:A) ratio on CT for all subjects with WSPH group 3 PH, matched disease comparators, and healthy controls in the Pulmonary Vascular Disease Phenomics (PVDOMICS) cohort. PH and comparator subjects were categorized by group 3 etiology into obstructive (including chronic obstructive pulmonary disease [COPD] and cystic fibrosis), interstitial (including idiopathic pulmonary fibrosis, unspecified interstitial lung disease, combined pulmonary fibrosis and emphysema, and chronic hypersensitivity pneumonitis), and non-parenchymal (including obesity hypoventilation syndrome, obstructive sleep apnea, and extrinsic restrictive disease) subgroups. Primary outcome was mPAP on right heart catheterization (RHC). Association with mPAP was evaluated using multivariable linear regression adjusted for age, sex, and BMI. Results 339 subjects met inclusion criteria (101 WSPH group 3 PH, 153 disease comparators, 85 healthy controls). 83 subjects had obstructive disease, 125 had interstitial disease, and 46 had non-parenchymal disease. PA diameter and PA:A were associated with mPAP in all subjects and in each subgroup (p < 0.001; see figure 1). The association was notably stronger in the non-parenchymal group (ρ = 0.707 for diameter, 0.750 for PA:A) compared to obstructive (ρ = 0.566 for diameter, 0.529 for PA:A) and interstitial (ρ = 0.432 for diameter, 0.373 for PA:A) groups. Change in PA size between 25th and 75th percentile mPAP was lower in the interstitial group (3.88 mm, ratio 0.12) than in the obstructive (4.88 mm, ratio 0.17) and non-parenchymal (4.80 mm, ratio 0.19) groups (see figure 1). Conclusions PA size on CT is associated with mPAP in subjects with chronic lung disease with and without PH. This association is strongest in subjects without parenchymal lung disease but with features of hypercarbia or hypoxia alone. These data suggest that features of parenchymal lung disease in certain patients may limit expected PA dilation in response to elevated PA pressures. Further study is needed regarding the implications of these findings for early identification of PH in patients with chronic lung disease. This abstract is funded by: The NHLBI and Pulmonary Hypertension Association
Benchmarking Surgical Outcomes for Endoscopic Transnasal Craniopharyngioma Resection: Implications for Clinical Practice From the RAPID Consortium
Tenhoeve, Samuel A. , Orton, Cody, Gautam, Diwas, Silverstein, Julie M., Kim, Albert H., Evans, James J., Barkhoudarian, Garni, Fernandez-Miranda, Juan C., Pacione, Donato , Kim, Won, Bergsneider, Marvin, Zada, Gabriel, Kshettry, Varun R., Wu, Kyle C., Prevedello, Daniel M., Benjamin, Carolina G., Gompel, Jamie Van, Catalino, Michael P., Mamelak, Adam N., Zwagerman, Nathan T., Cheok, Stephanie K., Little, Andrew S., Mendoza, Michelle Magana, Zenonos, Georgios A., Gardner, Paul A., Karsy, Michael, Morshed, Ramin A., Blackburn, Spiros L., Mukherjee, Debraj, Beer-Furlan, Andre, Couldwell, William T., Karsy, Michael , Van Gompel, Jamie, Palit, Sandhya R. , Rennert, Robert C , Karsy, Michael , Orton, Cody , Gautam, Diwas , Silverstein, Julie , Kim, Albert H , Evans, James J., Barkhoudarian, Garni , Fernandez‐Miranda, Juan C. , Bergsneider, Marvin , Chicoine, Michael , Zada, Gabriel , Kshettry, Varun R. , Prevedello, Daniel M. , Gompel, Jamie J. Van , Catalino, Michael Paul, Mamelak, Adam N, Zwagerman, Nathan T. , Cheok, Stephanie , Little, Andrew S. , Zenonos, Georgios A. , Gardner, Paul A. , Morshed, Ramin A. , Blackburn, Spiros L., Mukherjee, Debraj , Beer‐Furlan, André , Couldwell, William T.

Mayo Clinic

Operative Neurosurgery | May 13, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1227/ons.0000000000002055 | PMID 42138611 Get It

BACKGROUND AND OBJECTIVES: Craniopharyngiomas are complex intracranial tumors that pose significant challenges in surgical management. We aimed to develop risk-stratified surgical outcome benchmarks for adult patients undergoing endoscopic craniopharyngioma resection by using the Registry of Adenomas of the Pituitary and Related Disorders database to facilitate comparisons across institutions and guide clinical decision-making. METHODS: A retrospective cohort of adult patients (18 years and older) with craniopharyngioma undergoing a first-time endoscopic transnasal surgery across 14 academic centers in the United States was analyzed using data collected from 2011 to 2024. Patients were stratified into low-risk and high-risk cohorts based on criteria including age, body mass index, selected tumor characteristics (size, infundibular relationship, intraventricular extension), and previous radiation. Surgical outcomes were analyzed, and benchmarking ranges were defined using the established methodology. RESULTS: The overall cohort included 318 patients with a mean age of 50 years. Upon benchmarking analysis (50th-75th percentile performance), low-risk patients (n = 136) had a median length of stay of 4.0 to 6.0 days, 90-day readmission rates of 15.5% to 22.2%, skilled nursing facility discharge rates of <1.0%, postoperative cerebrospinal fluid leak incidence of <1.0% to 14.3%, gross total resection rates of 50.0% to 60.8%, new postoperative arginine vasopressin deficiency rates of 33.3% to 50.0%, and tumor progression/recurrence rates of <1.0% to 18.3% over a median follow-up period of 27.0 (IQR 10.5-56.5) months. Benchmarking ranges were proposed for each outcome to facilitate cross-institutional comparisons. CONCLUSION: Establishing surgical outcome benchmarks for adult patients undergoing craniopharyngioma resection using data from the Registry of Adenomas of the Pituitary and Related Disorders provides a framework for assessing surgical performance and guiding clinical decision-making. Benchmark ranges can inform institutional quality improvement efforts, perioperative risk stratification, and patient counseling regarding expected postoperative outcomes.